Prognosys Biosciences is a fast growing biotechnology company based in La Jolla, CA focused on the promising and rapidly developing field of personalized medicine. We are developing novel genomic and proteomic technologies to enable research discoveries and clinical applications. We have extensive expertise in the areas of assay development and biomarker discovery, as well as implementation of next-generation sequencing technologies for the analysis of complex biological systems.
Mark Chee, Ph.D.
President and CEO
Dr. Chee is internationally recognized as a leader in the field of genomics. He co-founded Illumina®, Inc., where he was VP of Genomics and Bioinformatics. Prior to that he was Director of Genetics Research at Affymetrix®, Inc. Dr. Chee has published ~40 scientific papers and is an inventor on over 50 issued U.S. patents. Dr. Chee is an advisor to the National Institutes of Health, serving on the National Advisory Council for Human Genome Research and the External Scientific Committee of The Cancer Genome Atlas project. He also serves on the Scientific Advisory Boards of Complete Genomics and Febit.